Literature DB >> 21940700

Validation of the Expanded Hammersmith Functional Motor Scale in spinal muscular atrophy type II and III.

Allan M Glanzman1, Jessica M O'Hagen, Michael P McDermott, William B Martens, Jean Flickinger, Susan Riley, Janet Quigley, Jacqueline Montes, Sally Dunaway, Liyong Deng, Wendy K Chung, Rabi Tawil, Basil T Darras, Darryl C De Vivo, Petra Kaufmann, Richard S Finkel.   

Abstract

The relationships between the Expanded Hammersmith Functional Motor Scale (HFMSE) and genotype and motor and respiratory outcomes were examined in patients with spinal muscular atrophy types II and III (n = 70). The correlation between the HFMSE and Gross Motor Function Measure was r = 0.98. Correlations between HFMSE and forced vital capacity (percentage of predicted normal) (n = 56) and a functional rating (n = 57) were r = 0.87 and r = 0.92, respectively. Correlations with strength were as follows: knee extension, r = 0.74 (n = 60); elbow flexion, r = 0.77 (n = 61); and knee flexion, r = 0.74 (n = 58). The HFMSE differentiated patients by SMN2 copy number (P = .0007); bi-level positive airway pressure use, <8 versus ≥8 hours/day (P < .0001); ambulatory status (P < .0001); and spinal muscular atrophy type (P < .0001). The HFMSE demonstrates significant associations with established measures of function, strength, and genotype, and discriminates patients based on function, diagnostic category, and bi-level positive airway pressure need. Time of administration averaged 12 minutes. The HFMSE is a valid, time-efficient outcome measure for clinical trials in spinal muscular atrophy types II and III.

Entities:  

Mesh:

Year:  2011        PMID: 21940700     DOI: 10.1177/0883073811420294

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  40 in total

1.  Rasch analysis of clinical outcome measures in spinal muscular atrophy.

Authors:  Stefan J Cano; Anna Mayhew; Allan M Glanzman; Kristin J Krosschell; Kathryn J Swoboda; Marion Main; Birgit F Steffensen; Carole Bérard; Françoise Girardot; Christine A M Payan; Eugenio Mercuri; Elena Mazzone; Bakri Elsheikh; Julaine Florence; Linda S Hynan; Susan T Iannaccone; Leslie L Nelson; Shree Pandya; Michael Rose; Charles Scott; Reza Sadjadi; Mackensie A Yore; Cynthia Joyce; John T Kissel
Journal:  Muscle Nerve       Date:  2013-07-26       Impact factor: 3.217

2.  Neurofilament light chain in serum of adolescent and adult SMA patients under treatment with nusinersen.

Authors:  Claudia D Wurster; Petra Steinacker; René Günther; Jan C Koch; Paul Lingor; Zeljko Uzelac; Simon Witzel; Kurt Wollinsky; Benedikt Winter; Alma Osmanovic; Olivia Schreiber-Katz; Rami Al Shweiki; Albert C Ludolph; Susanne Petri; Andreas Hermann; Markus Otto
Journal:  J Neurol       Date:  2019-09-24       Impact factor: 4.849

3.  Clinical and molecular cross-sectional study of a cohort of adult type III spinal muscular atrophy patients: clues from a biomarker study.

Authors:  Francesco D Tiziano; Rosa Lomastro; Lorena Di Pietro; Maria Barbara Pasanisi; Stefania Fiori; Carla Angelozzi; Emanuela Abiusi; Corrado Angelini; Gianni Sorarù; Alessandra Gaiani; Tiziana Mongini; Liliana Vercelli; Gessica Vasco; Giuseppe Vita; Gian Luca Vita; Sonia Messina; Luisa Politano; Luigia Passamano; Grazia Di Gregorio; Cristina Montomoli; Chiara Orsi; Angela Campanella; Renato Mantegazza; Lucia Morandi
Journal:  Eur J Hum Genet       Date:  2012-10-17       Impact factor: 4.246

4.  Prospective cohort study of spinal muscular atrophy types 2 and 3.

Authors:  Petra Kaufmann; Michael P McDermott; Basil T Darras; Richard S Finkel; Douglas M Sproule; Peter B Kang; Maryam Oskoui; Andrei Constantinescu; Clifton L Gooch; A Reghan Foley; Michele L Yang; Rabi Tawil; Wendy K Chung; William B Martens; Jacqueline Montes; Vanessa Battista; Jessica O'Hagen; Sally Dunaway; Jean Flickinger; Janet Quigley; Susan Riley; Allan M Glanzman; Maryjane Benton; Patricia A Ryan; Mark Punyanitya; Megan J Montgomery; Jonathan Marra; Benjamin Koo; Darryl C De Vivo
Journal:  Neurology       Date:  2012-10-17       Impact factor: 9.910

5.  Observational study of spinal muscular atrophy type I and implications for clinical trials.

Authors:  Richard S Finkel; Michael P McDermott; Petra Kaufmann; Basil T Darras; Wendy K Chung; Douglas M Sproule; Peter B Kang; A Reghan Foley; Michelle L Yang; William B Martens; Maryam Oskoui; Allan M Glanzman; Jean Flickinger; Jacqueline Montes; Sally Dunaway; Jessica O'Hagen; Janet Quigley; Susan Riley; Maryjane Benton; Patricia A Ryan; Megan Montgomery; Jonathan Marra; Clifton Gooch; Darryl C De Vivo
Journal:  Neurology       Date:  2014-07-30       Impact factor: 9.910

6.  The motor neuron response to SMN1 deficiency in spinal muscular atrophy.

Authors:  Peter B Kang; Clifton L Gooch; Michael P McDermott; Basil T Darras; Richard S Finkel; Michele L Yang; Douglas M Sproule; Wendy K Chung; Petra Kaufmann; Darryl C de Vivo
Journal:  Muscle Nerve       Date:  2014-05       Impact factor: 3.217

7.  Results of a two-year pilot study of clinical outcome measures in collagen VI- and laminin alpha2-related congenital muscular dystrophies.

Authors:  Katherine G Meilleur; Minal S Jain; Linda S Hynan; Ching-Yi Shieh; Eunice Kim; Melissa Waite; Michelle McGuire; Courtney Fiorini; Allan M Glanzman; Marion Main; Kristy Rose; Tina Duong; Roxanna Bendixen; Melody M Linton; Irene C Arveson; Carmel Nichols; Kelly Yang; Kenneth H Fischbeck; Kathryn R Wagner; Kathryn North; Ami Mankodi; Christopher Grunseich; Elizabeth J Hartnett; Michaele Smith; Sandra Donkervoort; Alice Schindler; Angela Kokkinis; Meganne Leach; A Reghan Foley; James Collins; Francesco Muntoni; Anne Rutkowski; Carsten G Bönnemann
Journal:  Neuromuscul Disord       Date:  2014-09-28       Impact factor: 4.296

8.  Motor Function Test Reliability During the NeuroNEXT Spinal Muscular Atrophy Infant Biomarker Study.

Authors:  Kristin J Krosschell; Michael Bosch; Leslie Nelson; Tina Duong; Linda P Lowes; Lindsay N Alfano; Danielle Benjamin; Terri B Carry; Ginger Devine; Carolyn Kelley; Rebecca Gadekan; Elizabeth C Malkus; Amy Pasternak; Stephanie Provance-Orr; Lynne Roemeiser-Logan; Alina Nicorici; Donata Trussell; Sally Dunaway Young; Jennifer R Fetterman; Jacqueline Montes; Penny J Powers; Rebecca Quinones; Janet Quigley; Christopher S Coffey; Jon W Yankey; Amy Bartlett; John T Kissel; Stephen J Kolb
Journal:  J Neuromuscul Dis       Date:  2018

9.  Pilot study of population-based newborn screening for spinal muscular atrophy in New York state.

Authors:  Jennifer N Kraszewski; Denise M Kay; Colleen F Stevens; Carrie Koval; Bianca Haser; Veronica Ortiz; Anthony Albertorio; Lilian L Cohen; Ritu Jain; Sarah P Andrew; Sally Dunaway Young; Nicole M LaMarca; Darryl C De Vivo; Michele Caggana; Wendy K Chung
Journal:  Genet Med       Date:  2017-10-12       Impact factor: 8.822

10.  International Workshop:: Outcome measures and clinical trial readiness in primary mitochondrial myopathies in children and adults. Consensus recommendations. 16-18 November 2016, Rome, Italy.

Authors:  Michelangelo Mancuso; Robert McFarland; Thomas Klopstock; Michio Hirano
Journal:  Neuromuscul Disord       Date:  2017-09-08       Impact factor: 4.296

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.